Literature DB >> 8687036

Suppression of hydroxyl radical formation and protection of nigral neurons by l-deprenyl (selegiline).

R M Wu1, D L Murphy, C C Chiueh.   

Abstract

The present study clearly demonstrated that l-deprenyl confers a substantial protective effect against MPP+ in the substantia nigra zona compacta in vivo. 32.39. The protection provided by l-deprenyl may not depend on its inhibition of type B monoamine oxidase. A unique antioxidant property of l-deprenyl by suppression of cycotoxic. OH formation and associated oxidative damage induced by MPP+ in the A9 melanized nigral neurons may contribute to the protection against MPP+ toxicity in the nigrostriatal system. The likelihood that l-deprenyl may confer neuroprotection against MPP+ toxicity through antioxidant effect is further strongly supported by our recent data that U-78517F (2-methlaminochromans) a potent inhibitor of ironcatalyzed lipid peroxidation, and DMSO an effective. OH scavenger also protect nigral neurons against MPP(+)-induced severe oxidative injury in the substantia nigra. This putative antioxidant effect of deprenyl may explore another mechanism which may in part contribute to its overt neuroprotection against several toxins, including 6-OHDA, DSP-4, and MPTP, and the possible clinical effects on slowing the neuronal degeneration in early Parkinson's disease, Alzheimer's disorder and even senescent changes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8687036     DOI: 10.1111/j.1749-6632.1996.tb39078.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals.

Authors:  C C Chiueh; T Andoh; A R Lai; E Lai; G Krishna
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 2.  Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Authors:  Éva Szökő; Tamás Tábi; Peter Riederer; László Vécsei; Kálmán Magyar
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

3.  Age-related protective effect of deprenyl on changes in the levels of diagnostic marker enzymes and antioxidant defense enzymes activities in cerebellar tissue in Wistar rats.

Authors:  Manju V Subramanian; T J James
Journal:  Cell Stress Chaperones       Date:  2010-03-13       Impact factor: 3.667

Review 4.  Tyrosine hydroxylase and Parkinson's disease.

Authors:  J Haavik; K Toska
Journal:  Mol Neurobiol       Date:  1998-06       Impact factor: 5.590

Review 5.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 6.  An inducible MAO-B mouse model of Parkinson's disease: a tool towards better understanding basic disease mechanisms and developing novel therapeutics.

Authors:  Manish Chamoli; Shankar J Chinta; Julie K Andersen
Journal:  J Neural Transm (Vienna)       Date:  2018-04-30       Impact factor: 3.575

7.  MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology.

Authors:  Jyothi K Mallajosyula; Deepinder Kaur; Shankar J Chinta; Subramanian Rajagopalan; Anand Rane; David G Nicholls; Donato A Di Monte; Heather Macarthur; Julie K Andersen
Journal:  PLoS One       Date:  2008-02-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.